Aug
12
Mon
2013
Delegate Talk: Development of a Phototrophic Microbial Fuel Cell with sacrificial electrodes and a novel proton exchange matrix @ Sathyam Hall
Aug 12 @ 2:40 pm – 2:55 pm

ajithAjith Madhavan
Assistant Professor, School of Biotechnology, Amrita University


Development of a Phototrophic Microbial Fuel Cell with sacrificial electrodes and a novel proton exchange matrix

If micro organisms can solve Sudoku and possibly have feelings, who is to say that they cannot also solve the planet’s energy crisis? Mr. Madhavan employs micro organisms to produce energy using microbial fuel cell (MFC). Micro organisms go through a series of cycles and pathways in order to survive, including the Electron Transport Pathway (ETP) in which bacteria release electrons which can be tapped as energy. In a two-chambered MFC, micro organisms interact with an anode in one chamber and in the presence of an oxidizing agent in the cathodic chamber scavenges electrons from the cathode. The two chambers are connected by an external circuit and connected to a load. In between the two chambers is a proton exchange membrane (PEM) which transports protons from the second chamber to the first and acts as a barrier for electrons. Therefore, a renewable source of energy can be maintained by just providing your bacterial culture with the proper nutrients to thrive and remain happy and satisfied (assuming they have emotions).

Mr. Madhavan has done extensive work on such MFCs and has experimented with various micro organisms and substrates to achieve high energy production. The phototropic MFC Mr. Madhavan designed using Synechococcus elongates using waste water as a substrate was able to generate approximately 10 mȦ and 1 volt of electricity. Other research in this area has even shown that using human urine can be used as a substrate for certain bacteria to produce enough energy to charge a mobile phone.

Although this microbial technology seems to be the “next big thing” (despite their small size) when it comes to renewable energy sources there is still a lot of work to be done before these bacteria batteries hit the market. As of now the MFCs are still much less efficient than solar cells and the search for the perfect bacteria and substrate continues.

Aug
13
Tue
2013
Invited Talk: Cancer Stem Cells – Target Colon Cancer @ Acharya Hall
Aug 13 @ 4:25 pm – 5:04 pm

ShrikantShrikant Anant, Ph.D.
The Department of Molecular & Integrative Physiology, Kansas University Medical Center, USA


Cancer Stem Cells: Target Colon Cancers

Shrikant Anant, Deep Kwatra and Dharmalingam Subramaniam

Colon cancer is a leading cause of cancer related deaths in the US, and its rate is increasing at an alarming rate in lndia. Recent studies have suggested the drug resistance role for a mall number of cells within a tumor called cancer stem cells. We identified the colon cancer stem cell marker DCLK1, a member of the protein kinase superfamily and the doublecortin family. The protein encodes a Cterminal serinethreonine protein kinase domain, which shows substantial homology to Ca2calmodulindependent protein kinase. Our current studies have been to identify compounds that can either affect DCLK1 expression or inhibits its activity as a way to inhibit cancer stem cells. Honokiol is a biphenolic compound that has been used in the traditional Chinese Medicine for treating various ailments. In vitro kinase assays with recombinant DCLK1 demonstrated that honokiol inhibits its kinase activity in a dose dependent manner. We therefore determined the effect of honokiol on stem cells. One method to look at effects on stem cells is perform a spheroid assay, where spheroids formation is suggested to maintain stemlike characteristic of cancer cells. Honokiol significantly suppressed colonosphere formation of two colon cancer cell lines HCT116 and SW480. Flow cytometry studies confirmed that honokiol reduced the number of DCLK1cells. A critical signaling pathway known to modulate intestinal stem cell proliferation is the Hippo signaling pathway, and deregulation of the pathway leads to tumor development. DCLK1cells had high levels of YAP1, the nuclear target of Hippo signaling. We determined the effect of honokiol on components of the hipposignaling pathway. Honokiol reduced the phosphorylation of Mst1/2, Lats1/2 and YAP1. Furthermore, honokiol treatment resulted in downregulation of YAPTEAD complex protein TEAD-1. Ectopic expression of the TEAD-1 partially rescued the cells from honokiol mediated growth suppression. To determine the effect of honokiol on tumor growth in vivo, nude mice harboring HCT116 tumor xenografts in their flanks were administered the compound intraperitoneally every day for 21 days. Honokiol treatment significantly inhibited tumor xenograft growth. Western blot and immunohistochemistry analyses demonstrated significant inhibition in the expression of stem marker and Hippo signaling proteins in the honokioltreated xenograft tissues. Taken together, these data suggest that honokiol is a potent inhibitor of colon cancer that targets DCLK1 stem cells by inhibiting Hippo signaling pathway.

Aug
14
Wed
2013
Invited Talk: A draft map of the human proteome @ Amriteshwari Hall
Aug 14 @ 10:42 am – 11:30 am

akhileshAkhilesh Pandey, Ph.D.
Professor, Johns Hopkins University School of Medicine, Baltimore, USA


A draft map of the human proteome

We have generated a draft map of the human proteome through a systematic and comprehensive analysis of normal human adult tissues, fetal tissues and hematopoietic cells as an India-US initiative. This unique dataset was generated from 30 histologically normal adult tissues, fetal tissues and purified primary hematopoietic cells that were analyzed at high resolution in the MS mode and by HCD fragmentation in the MS/MS mode on LTQ-Orbitrap Velos/Elite mass spectrometers. This dataset was searched against a 6-frame translation of the human genome and RNA-Seq transcripts in addition to standard protein databases. In addition to confirming a large majority (>16,000) of the annotated protein-coding genes in humans, we obtained novel information at multiple levels: novel protein-coding genes, unannotated exons, novel splice sites, proof of translation of pseudogenes (i.e. genes incorrectly annotated as pseudogenes), fused genes, SNPs encoded in proteins and novel N-termini to name a few. Many proteins identified in this study were identified by proteomic methods for the first time (e.g. hypothetical proteins or proteins annotated based solely on their chromosomal location). We have generated a catalog of proteins that show a more tissue-restricted pattern of expression, which should serve as the basis for pursuing biomarkers for diseases pertaining to specific organs. This study also provides one of the largest sets of proteotypic peptides for use in developing MRM assays for human proteins. Identification of several novel protein-coding regions in the human genome underscores the importance of systematic characterization of the human proteome and accurate annotation of protein-coding genes. This comprehensive dataset will complement other global HUPO initiatives using antibody-based as well as MRM mass spectrometry-based strategies. Finally, we believe that this dataset will become a reference set for use as a spectral library as well as for interesting interrogations pertaining to biomedical as well as bioinformatics questions.

Akhilesh (2)